The EU butts heads with Big Pharma to make medicines cheaper

By HEOR Staff Writer

February 2, 2023

EU Pharmaceutical Regulations Proposal

The new EU proposal to revamp its pharmaceutical regulations. The main aim is to give people a better and more affordable access to medicines.

From what I can see, there are mixed feelings about the proposal. On one hand, consumer groups and civil society organizations are applauding the EU’s efforts to make medicines more accessible. On the other hand, the pharmaceutical industry is a bit skeptical.

So, what’s in the proposal? Well, the EU is looking to shorten the period in which pharmaceutical companies can sell their medicines without competition from 10 years to just 8 years. They’re also working towards closing the gap in access to medicines among different EU member states.

It’s interesting to see how this will all play out. What are your thoughts on the EU Pharmaceutical Regulations Proposal?

Reference url

Recent Posts

Portugal Biotech Growth
Catalysts Driving Portugal Biotech Growth in Europe

By João L. Carapinha

July 2, 2026

Portugal Biotech Growth is reshaping the country’s standing in European life sciences, delivering a compact yet high-potential ecosystem anchored by world-class universities in Porto and Coimbra, innovation parks, and forward-looking industrial policy. Once overshadowed by larger neighbours, Port...
health innovation access
Widespread Barriers to Health Innovation Access in Portugal

By João L. Carapinha

July 2, 2026

Health innovation access in Portugal is widely viewed as inadequate, with 80% of patient associations rating it as reasonable or poor. Only 14% say most relevant innovations reach patients without significant restrictions, according to a Medjournal.pt investigation. The gaps are most acute in ...
orphan drug designation zoci
Orphan Drug Designation Zoci Enhances Treatment Prospects for Pulmonary Neuroendocrine Carcinomas

By João L. Carapinha

July 1, 2026

The European Medicines Agency has granted orphan drug designation for zocilurtatug pelitecan, an investigational DLL3-targeted antibody-drug conjugate, based on ...